https://www.selleckchem.com/pr....oducts/beta-glycerop
Immune checkpoint inhibitors (ICI) represent the backbone treatment for advanced non-small cell lung cancer (NSCLC). Emerging data suggest that increased gut microbiome diversity is associated with favorable response to ICI and that antibiotic-induced dysbiosis is associated with deleterious outcomes. F-FDG physiologic colonic uptake on PET/CT increases following treatment with antibiotics (AT and could act as a surrogate marker for microbiome composition and predict prognosis. The aim of this study w
Like
Comment
Share
